STOCK TITAN

scPharmaceuticals Inc - SCPH STOCK NEWS

Welcome to our dedicated news page for scPharmaceuticals (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect scPharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of scPharmaceuticals's position in the market.

Rhea-AI Summary
scPharmaceuticals has enrolled the first participant in the pivotal pharmacokinetic study of SCP-111 (furosemide 80 mg/mL) auto-injector, aiming to complement the FDA approved On-body Infusor. The Company anticipates topline data in Q3 2024, with potential sNDA submission by year-end 2024. Expansion initiatives for heart failure and chronic kidney disease are also in progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
scPharmaceuticals Inc. (SCPH) reported strong financial results for Q4 2023 with net FUROSCIX revenue of $6.1 million, a 61% sequential growth. Full-year revenue reached $13.6 million. The company ended 2023 with $76 million in cash. scPharmaceuticals plans to expand FUROSCIX indications, including a pivotal PK study and an sNDA submission to the FDA. Despite revenue growth, the company reported a net loss of $13.8 million in Q4 and $54.8 million for the full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
-
Rhea-AI Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) will host a conference call and webcast to discuss financial results for Q4 and full-year 2023, along with a business update on March 13, 2024. Participants can dial in or access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
Rhea-AI Summary
scPharmaceuticals Inc. (SCPH) announces CEO's participation in investor conferences to discuss the company's developments and future prospects. The events include TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. Investors can access live webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million, with full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million. Inventory levels at the end of Q4 2023 are consistent with Q3 2023. Unaudited cash, cash equivalents, and short-term investments are approximately $76 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
-
Rhea-AI Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) reports net FUROSCIX revenue of $3.8 million for Q3 2023. The company ended the quarter with $90.2 million in cash, cash equivalents, and short-term investments. Positive demand trends for FUROSCIX were observed, with significant agreements and expansions in access to the product. The company also announced FDA feedback for potential product developments and indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.74%
Tags
Rhea-AI Summary
scPharmaceuticals Inc. will host a conference call and webcast on November 8, 2023, to discuss the financial results for the third quarter of 2023 and provide a business update. The call will be accessible through dial-in numbers or the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
-
Rhea-AI Summary
scPharmaceuticals Inc. announced that its CEO will participate in two upcoming investor conferences. The first conference is the Jefferies London Healthcare Conference on November 14, 2023, where there will be a fireside chat at 12:00pm GMT. The second conference is the Craig-Hallum 14th Annual Alpha Select Conference on November 16, 2023, where there will be investor one-on-one meetings only. A webcast of the Jefferies' fireside chat will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
conferences
-
Rhea-AI Summary
scPharmaceuticals grants inducement equity grants to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
none
Rhea-AI Summary
scPharmaceuticals plans to expand the FUROSCIX franchise with an 80mg/1ml auto-injector, potentially reducing manufacturing costs and providing environmental advantages. FDA confirms no additional clinical data needed for label expansion of FUROSCIX into chronic kidney disease. Positive growth initiatives for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
scPharmaceuticals Inc

Nasdaq:SCPH

SCPH Rankings

SCPH Stock Data

177.75M
18.32M
6.59%
75.87%
12.8%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Burlington

About SCPH

scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.